---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000033"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:37:57.997766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma Q1 net loss $10.3M; cash $84M; initiates two Phase 2 rademikibart trials

## Summary
- Cash, equivalents and ST investments $84.0M as of March 31, 2025; runway into 2027.
- Net loss $10.3M ($0.19/share) vs $8.7M ($0.16) in Q1 2024; R&D expense $6.6M, down $2.1M YoY.
- Initiated Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart; topline data expected 1H 2026.
- Phase 2 data published in AJRCCM showed 420 mL FEV1 improvement vs placebo in eosinophilic asthma.

## SEC filing metadata
- accession: 0001835268-25-000033
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/0001835268-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/cntb-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000033
- JSON: https://secwatch.observer/filing/0001835268-25-000033.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.